drugset / Trial / NCT01013142
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bedoradrine | Small molecule | 300 ug | Intravenous |
| Subject | bedoradrine | Small molecule | 600 ug | Intravenous |
| Subject | bedoradrine | Small molecule | 1200 ug | Intravenous |